published by john wiley  sons ltd.147analysis 1.18. comparison 1 probiotics versus control outcome 18 incidence of infection complete case.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 18 incidence of infection complete caseanalysis 1.19. comparison 1 probiotics versus control outcome 19 incidence of infection subgroup risk of bias.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 19 incidence of infection subgroup risk of biasanalysis 1.20. comparison 1 probiotics versus control outcome 20 incidence of infection inpatient versus outpatient.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 20 incidence of infection inpatient versus outpatientstudy or subgroupexperimentalcontrolrisk ratioweightrisk ratioheterogeneity not applicabletest for overall effect z  0.03 p  0.97nnnnm-hrandom95cim-hrandom95citotal 95 ci587545100.0 0.85  0.66 1.09 total events 94 experimental 97 controlheterogeneity tau2  0.0 chi2  5.59 df  10 p  0.85 i2 0.0 test for overall effect z  1.26 p  0.21test for subgroup differences chi2  1.13 df  2 p  0.57 i2 0.00.010.1110100favours probioticsfavours controlanalysis 1.21. comparison 1 probiotics versus control outcome 21 incidence of infection species all.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 21 incidence of infection species allstudy or subgroupexperimentalcontrolrisk ratioweightrisk ratio1 lactobacillus reuteri dsm 17938nnnnm-hrandom95cim-hrandom95citotal events 14 experimental 15 control heterogeneity not applicabletest for overall effect z  0.29 p  0.77 2 clostridium butyricumimase 2008212171.3 1.17  0.13 10.66 shimbo 2005018017not estimablesubtotal 95 ci30241.3 1.17  0.13 10.66 total events 2 experimental 1 control heterogeneity not applicabletest for overall effect z  0.14 p  0.890.010.1110100favours probioticsfavours controlcontinued .

published by john wiley  sons ltd.145analysis 1.16. comparison 1 probiotics versus control outcome 16 incidence cdad 3-5 baseline risk rob.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 16 incidence cdad 3-5 baseline risk robstudy or subgroupexperimentalcontrolrisk ratioweightrisk ratiom-hrandom95m-hrandom95analysis 1.17. comparison 1 probiotics versus control outcome 17 incidence cdad 5 baseline risk rob.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 17 incidence cdad 5 baseline risk robtotal events 15 experimental 47 controlheterogeneity tau2  0.0 chi2  2.21 df  4 p  0.70 i2 0.0 test for overall effect z  4.87 p  0.000012 unclearhightotal events 28 experimental 79 controlheterogeneity tau2  0.0 chi2  2.37 df  7 p  0.94 i2 0.0 test for overall effect z  5.15 p  0.00001total 95 ci13701084100.0 0.30  0.21 0.42 total events 43 experimental 126 controlheterogeneity tau2  0.0 chi2  5.14 df  12 p  0.95 i2 0.0 test for overall effect z  7.05 p  0.00001test for subgroup differences chi2  0.56 df  1 p  0.45 i2 0.00.010.1110100favours probioticsfavours controlprobiotics for the prevention of clostridium difficile-associated diarrhea in adults and children review copyright c 2017 the cochrane collaboration.

published by john wiley  sons ltd.144analysis 1.15. comparison 1 probiotics versus control outcome 15 incidence cdad 0-2 baseline risk rob.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 15 incidence cdad 0-2 baseline risk robtotal events 16 probiotics 22 controlheterogeneity tau2  0.0 chi2  0.08 df  2 p  0.96 i2 0.0 test for overall effect z  0.99 p  0.322 highuncleartotal events 8 probiotics 9 controlheterogeneity tau2  0.0 chi2  4.16 df  6 p  0.65 i2 0.0 test for overall effect z  0.24 p  0.81total 95 ci29682877100.0 0.77  0.45 1.32 total events 24 probiotics 31 controlheterogeneity tau2  0.0 chi2  4.36 df  9 p  0.89 i2 0.0 test for overall effect z  0.95 p  0.34test for subgroup differences chi2  0.12 df  1 p  0.73 i2 0.00.010.1110100favours probioticsfavours controlprobiotics for the prevention of clostridium difficile-associated diarrhea in adults and children review copyright c 2017 the cochrane collaboration.

published by john wiley  sons ltd.153analysis 1.22. comparison 1 probiotics versus control outcome 22 incidence of infection subgroup species lgg versus sb.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 22 incidence of infection subgroup species lgg versus sbstudy or subgroupprobioticscontrolrisk ratioweightrisk rationnnnm-hrandom95cim-hrandom95cianalysis 1.23. comparison 1 probiotics versus control outcome 23 incidence of infection adult versus child.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 23 incidence of infection adult versus childanalysis 1.24. comparison 1 probiotics versus control outcome 24 adverse events complete case.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 24 adverse events complete casestudy or subgroupexperimentalcontrolrisk ratioweightrisk rationnnnm-hrandom95cim-hrandom95ciallen 20132941470284147113.1 1.04  0.90 1.20 arvola 1999061058not estimablebeausoleil 2007214420456.6 1.07  0.68 1.68 bravo 20083414451.1 0.82  0.20 3.46 cindoruk 20074162626212.4 0.66  0.56 0.79 duman 2005319641801.0 0.69  0.16 3.04 ehrhardt 201618146121463.7 1.50  0.75 3.00 fominykh 2013080040not estimablegao 201011712840.4 0.25  0.02 2.67 hickson 2007057056not estimableimase 2008112370.5 0.19  0.02 1.53 klarin 2008022022not estimablekoning 20081519171910.0 0.88  0.67 1.17 kotowska 200501190127not estimablelonnermark 20103803830.9 1.04  0.22 4.99 mcfarland 199509312920.3 0.04  0.00 0.66 miller 2008a2954940.8 0.49  0.09 2.64 miller 2008b415601550.3 8.94  0.49 164.71 nord 199791110127.9 0.98  0.67 1.43 ouwehand 201414304121443.4 0.55  0.26 1.16 pozzoni 20124110635988.3 1.08  0.76 1.55 psaradellis 20109021610322111.6 0.89  0.72 1.10 ruszczynski 200801200120not estimable0.010.1110100favours experimentalfavours controlcontinued .

published by john wiley  sons ltd.172analysis 1.32. comparison 1 probiotics versus control outcome 32 adverse events species lgg versus la  lc.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 32 adverse events species lgg versus la  lcanalysis 1.33. comparison 1 probiotics versus control outcome 33 adverse events inpatient versus outpatient.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 33 adverse events inpatient versus outpatienttotal events 448 experimental 454 controlheterogeneity tau2  0.05 chi2  19.98 df  11 p  0.05 i2 45 test for overall effect z  0.94 p  0.352 outpatientbravo 20083414451.0 0.82  0.20 3.46 duman 2005319641800.9 0.69  0.16 3.04 0.010.1110100favours probioticsfavours controlcontinued .

published by john wiley  sons ltd.201analysis 1.47. comparison 1 probiotics versus control outcome 47 incidence aad child rob.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 47 incidence aad child robtotal events 14 experimental 51 controlheterogeneity tau2  0.0 chi2  0.05 df  1 p  0.83 i2 0.0 test for overall effect z  4.48 p  0.00001total 95 ci566575100.0 0.38  0.29 0.49 total events 56 experimental 156 controlheterogeneity tau2  0.0 chi2  2.31 df  5 p  0.80 i2 0.0 test for overall effect z  7.27 p  0.00001test for subgroup differences chi2  1.40 df  1 p  0.24 i2 290.010.1110100favours probioticsfavours controlprobiotics for the prevention of clostridium difficile-associated diarrhea in adults and children review copyright c 2017 the cochrane collaboration.

published by john wiley  sons ltd.170study or subgroupexperimentalcontrolrisk ratioweightrisk rationnnnm-hrandom95cim-hrandom95citotal 95 ci43293976100.0 0.83  0.71 0.97 total events 620 experimental 677 controlheterogeneity tau2  0.04 chi2  41.48 df  21 p  0.005 i2 49 test for overall effect z  2.30 p  0.021test for subgroup differences chi2  18.95 df  10 p  0.04 i2 470.010.1110100favours probioticsfavours controlanalysis 1.31. comparison 1 probiotics versus control outcome 31 adverse events species lgg versus sb.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 31 adverse events species lgg versus sbstudy or subgroupexperimentalcontrolrisk ratioweightrisk ratiolggnnnnm-hrandom95cim-hrandom95ciarvola 1999061058not estimablemiller 2008a2954942.6 0.49  0.09 2.64 miller 2008b415601550.9 8.94  0.49 164.71 ruszczynski 200801200120not estimablesiitonen 199028383.2 0.67  0.15 2.98 thomas 2001371335213425.3 0.72  0.51 1.01 subtotal 95 ci57356932.1 0.74  0.48 1.14 total events 45 experimental 59 controlheterogeneity tau2  0.03 chi2  3.18 df  3 p  0.36 i2 6 test for overall effect z  1.39 p  0.17sbbravo 20083414453.5 0.82  0.20 3.46 0.010.1110100favours probioticsfavours controlcontinued .

published by john wiley  sons ltd.193study or subgroupexperimentalcontrolrisk ratioweightrisk rationnnnm-hrandom95cim-hrandom95cistudy or subgroupexperimentalcontrolrisk ratioweightrisk rationnnnm-hrandom95cim-hrandom95cisubtotal 95 ci8040not estimabletotal events 0 experimental 0 control heterogeneity not applicabletest for overall effect not applicabletotal 95 ci28532506100.0 0.55  0.46 0.65 total events 382 experimental 596 controlheterogeneity tau2  0.09 chi2  52.78 df  29 p  0.004 i2 45 test for overall effect z  6.77 p  0.00001test for subgroup differences chi2  16.58 df  14 p  0.28 i2 160.010.1110100favours experimentalfavours controlanalysis 1.43. comparison 1 probiotics versus control outcome 43 incidence aad species lgg versus sb.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 43 incidence aad species lgg versus sbtotal events 59 experimental 73 controlheterogeneity tau2  0.26 chi2  7.90 df  3 p  0.05 i2 62 test for overall effect z  0.88 p  0.382 sb0.010.1110100favours experimentalfavours controlcontinued .

published by john wiley  sons ltd.202analysis 1.48. comparison 1 probiotics versus control outcome 48 length of hospital stay complete case.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 48 length of hospital stay complete caseheterogeneity tau2  0.0 chi2  2.44 df  3 p  0.49 i2 0.0 test for overall effect z  0.39 p  0.69test for subgroup differences not applicable-100-50050100favours experimentalfavours controla p p e n d i c e sappendix 1. search strategiesembaserandom.mp.factorial.mp.crossover or cross over or cross-over.mp.placebo.mp.single blind.mp.double blind.mp.triple blind.mp.singl adj blind.mp.double adj blind.mp.tripl adj blind.mp.assign.mp.allocat.mp.crossover proceduredouble blind proceduresingle blind proceduretriple blind procedureprobiotics for the prevention of clostridium difficile-associated diarrhea in adults and children review203randomized controlled trial 18. or1-1719.

published by john wiley  sons ltd.196la  lc.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 44 incidence aad species lgg versus la  lctotal events 91 experimental 118 controlheterogeneity tau2  0.03 chi2  3.24 df  2 p  0.20 i2 38 test for overall effect z  3.26 p  0.0011total 95 ci902821100.0 0.65  0.47 0.91 total events 150 experimental 191 controlheterogeneity tau2  0.10 chi2  13.94 df  6 p  0.03 i2 57 test for overall effect z  2.55 p  0.011test for subgroup differences chi2  0.43 df  1 p  0.51 i2 0.00.010.1110100favours experimentalfavours controlprobiotics for the prevention of clostridium difficile-associated diarrhea in adults and children review copyright c 2017 the cochrane collaboration.

published by john wiley  sons ltd.132study or subgroupexperimentalcontrolrisk ratioweightrisk rationnnnm-hrandom95cim-hrandom95cistudy or subgroupexperimentalcontrolrisk ratioweightrisk rationnnnm-hrandom95cim-hrandom95cistudy or subgroupexperimentalcontrolrisk ratioweightrisk rationnnnm-hrandom95cim-hrandom95cisubtotal 95 ci8040not estimabletotal events 0 experimental 0 control heterogeneity not applicabletest for overall effect not applicabletotal 95 ci45254147100.0 0.40  0.30 0.52 total events 70 experimental 164 controlheterogeneity tau2  0.0 chi2  19.06 df  25 p  0.79 i2 0.0 test for overall effect z  6.54 p  0.00001test for subgroup differences chi2  12.13 df  12 p  0.43 i2 10.0050.1110200favours experimentalfavours controlanalysis 1.9. comparison 1 probiotics versus control outcome 9 incidence cdad subgroup species lgg versus sb.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 9 incidence cdad subgroup species lgg versus sbstudy or subgroupexperimentalcontrolrisk ratioweightrisk ratiolactobacillus ggnnnnm-hrandom95cim-hrandom95ciarvola 19991611583.2 0.95  0.06 14.85 miller 2008a49579416.7 0.57  0.17 1.87 miller 2008b215701592.6 5.06  0.25 104.63 ruszczynski 20083120712013.5 0.43  0.11 1.62 thomas 2001213331347.6 0.67  0.11 3.96 subtotal 95 ci56656543.6 0.63  0.30 1.33 total events 12 experimental 18 controlheterogeneity tau2  0.0 chi2  2.29 df  4 p  0.68 i2 0.00.0050.1110200favours experimentalfavours controlcontinued .

published by john wiley  sons ltd.141analysis 1.13. comparison 1 probiotics versus control outcome 13 incidence cdad baseline risk.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 13 incidence cdad baseline risktotal events 24 experimental 31 controlheterogeneity tau2  0.0 chi2  4.36 df  9 p  0.89 i2 0.0 test for overall effect z  0.95 p  0.343-5 baseline riskheterogeneity tau2  0.0 chi2  0.71 df  2 p  0.70 i2 0.0 test for overall effect z  1.04 p  0.300.010.1110100favours probioticsfavours controlcontinued .

published by john wiley  sons ltd.131analysis 1.8. comparison 1 probiotics versus control outcome 8 incidence cdad subgroup species all.review probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children comparison 1 probiotics versus controloutcome 8 incidence cdad subgroup species alltotal events 13 experimental 32 controlheterogeneity tau2  0.0 chi2  4.18 df  6 p  0.65 i2 0.0 test for overall effect z  2.67 p  0.00762 s. cerevisiaetotal events 12 experimental 18 controlheterogeneity tau2  0.0 chi2  2.26 df  4 p  0.69 i2 0.00.0050.1110200favours experimentalfavours controlcontinued .

published by john wiley  sons ltd.135study or subgroupexperimentalcontrolrisk ratioweightrisk ratiotest for overall effect z  1.21 p  0.23 2 s. boulardiinnnnm-hrandom95cim-hrandom95citotal events 13 experimental 32 controlheterogeneity tau2  0.0 chi2  4.21 df  6 p  0.65 i2 0.0 test for overall effect z  2.64 p  0.0084total 95 ci14881433100.0 0.50  0.31 0.82 total events 25 experimental 50 controlheterogeneity tau2  0.0 chi2  7.13 df  11 p  0.79 i2 0.0 test for overall effect z  2.78 p  0.0054test for subgroup differences chi2  0.69 df  1 p  0.41 i2 0.00.0050.1110200favours experimentalfavours controlprobiotics for the prevention of clostridium difficile-associated diarrhea in adults and children review copyright c 2017 the cochrane collaboration.

continuedstudy or subgroupexperimentalcontrolrisk ratioweightrisk rationnnnheterogeneity tau2  0.11 chi2  51.57 df  21 p  0.00022 i2 59 test for overall effect z  4.59 p  0.000012 childm-hrandom95cim-hrandom95citotal events 56 experimental 156 controlheterogeneity tau2  0.0 chi2  2.31 df  5 p  0.80 i2 0.0 test for overall effect z  7.27 p  0.00001total 95 ci42603917100.0 0.56  0.46 0.68 total events 532 experimental 739 controlheterogeneity tau2  0.14 chi2  73.19 df  27 p0.00001 i2 63 test for overall effect z  5.87 p  0.00001test for subgroup differences chi2  8.80 df  1 p  0.00 i2 890.010.1110100favours experimentalfavours controlprobiotics for the prevention of clostridium difficile-associated diarrhea in adults and children review copyright c 2017 the cochrane collaboration.

